CSE Bulletin: Consolidation - Lobe Sciences Ltd.

CSE Bulletin: Consolidation - Lobe Sciences Ltd.

lobe sciences ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares.

As a result, the outstanding common shares of the Issuer will be reduced to approximately 38,230,000 common shares.

Further to the Issuer's news release dated June 6, 2022, the record date has been changed to June 10, 2022.

Trading will remain halted June 9, 2022 and resume on a consolidated basis June 10, 2022.

The name and symbol will not change.

Please note that all open orders will be cancelled at the close of business on June 9, 2022. Dealers are reminded to re-enter their orders taking into account the share consolidation.

_________________________________

lobe sciences ltd. (l'« émetteur ») a annoncé un regroupement de ses actions ordinaires émises et en circulation sur la base d'une (1) action ordinaire post-regroupement pour six (6) actions ordinaires pré-regroupement.

Par conséquent, les actions ordinaires en circulation de l'Émetteur seront réduites à environ 38 230 000 actions ordinaires.

Suite au communiqué de presse de l'Emetteur du 6 juin 2022, la date d'enregistrement a été reportée au 10 juin 2022.

Les échanges resteront interrompus le 9 juin 2022 et reprendront sur une base consolidée le 10 juin 2022.
Le nom et le symbole ne changeront pas.

Veuillez noter que tous les ordres ouverts seront annulés à la fermeture des bureaux le 9 juin 2022. Il est rappelé aux concessionnaires de saisir à nouveau leurs ordres en tenant compte du regroupement d'actions.

Trading on a Consolidated Basis/Négociation sur une base consolidée:

Le 10 juin/June 2022

Record Date/Date d'enregistrement:

Le 10 juin/June 2022

Symbol/Symbole:

LOBE

NEW/NOUVEAU CUSIP:

53946V 20 6

NEW/NOUVEAU ISIN:

CA53946V 20 6 6

Old/Vieux CUSIP & ISIN:

53946V107/CA53946V1076

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com.

Pour toute question ou information complémentaire, veuillez contacter Listings au 416 367-7340 ou par courriel à: Listings@thecse.com.

News Provided by Newsfile via QuoteMedia

Spartan Metals

Spartan Metals Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Spartan Metals (TSXV:W)

Spartan Metals

Advancing US critical minerals resource through a high-grade past-producing tungsten-rubidium project in Nevada

Advancing US critical minerals resource through a high-grade past-producing tungsten-rubidium project in Nevada Keep Reading...
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2025

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs. Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent... Keep Reading...
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded... Keep Reading...
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based... Keep Reading...
Invion Executive Chair and CEO Thian Chew.

Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds

Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing,... Keep Reading...
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based... Keep Reading...
Spartan Metals

Spartan Metals Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News